Navigation Links
Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
Date:4/30/2008

461 +4.3%

United States 778 +44.6%

Other Countries 231 +32.0%

TOTAL 1,470 +27.3%

In the United States, sales of Plavix(R) (consolidated by Bristol Myers Squibb -- BMS) reached $1,142 million in the first quarter, versus $789 million in the first quarter of 2007 when the product was still affected by the presence of a generic version.

In Europe, net sales of Plavix(R) were up 4.3% at EURO 461 million, though sales are still being affected by Germany.

In addition, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) recently issued a positive opinion recommending approval of the 300mg tablet of Plavix(R). This positive opinion from the CHMP must be ratified by the European Commission in the coming months before final approval.

In the Other Countries region, Plavix(R) reported a strong advance in sales of 32.0% to EURO 231 million, supported by the product's success in Japan (net sales of EURO 28 million, compared with EURO 4 million in the first quarter of 2007).

Worldwide presence of Aprovel(R)/ Avapro(R)/ Karvea(R)

EURO million Q1 2008 Change on a comparable basis

Europe 245 +8.4%

United States 119 +8.2%

Other Countries 108 +22.7%

TOTAL 472 +11.3%

First-quarter worldwide sales of Aprovel(R)/Avapro(R)/Karvea(R) were up 11.3% at EURO 472 million.

Net sales by business segment -- Human Vaccines

First-quarter consolidated net sales for the Human Vaccines division rose by 2.8% to EURO 548 million.

Menactra(R) was the main growth driver, with net sales up 48.1% at EURO 99 million.

Net sales of Adacel(TM) (adult and
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Tubbs Jones Introduces Resolution Encouraging STD Prevention
2. New electronic health records demonstration project encouraging step says ACP
3. Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates
4. Digirad Corporation Reports Financial Results for First-Quarter 2008
5. Essilors 2008 First-Quarter Report
6. First-Quarter 2008 Results Teleconference/Webcast for VNUS Medical Technologies Interrupted Due to Technical Difficulties
7. Triple-S Management Corporation Schedules First-Quarter Earnings Release and Webcast
8. Cynosure to Announce First-Quarter 2008 Financial Results on April 29
9. VNUS Medical Technologies to Report First-Quarter 2008 Results and Webcast Teleconference on April 21
10. Hospira Hosts Conference Call for First-Quarter 2008 Earnings
11. Abbott Hosts Conference Call for First-Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... cells metastasize? Think of Sparta. , Ancient Greek warriors ... for the demands of battle on distant fields. Cancer ... to a new study revealing previously unknown differences between ... tumor site, and those that travel to other organs. ... metastasize is the primary cause of cancer-related death, understanding ...
(Date:9/21/2014)... 2014 Hundreds of Risperdal lawsuits ... Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard ... next monthly meeting has been scheduled for October ... “Our Firm is representing a number of plaintiffs ... We are pleased with its continued progress,” says ...
(Date:9/21/2014)... Best Cheap Hosting USA, one of the ... and GreenGeeks are the best Reseller hosting suppliers in ... hosting supplier. Actually, these companies have outperformed their competitors ... People can get the best web hosting at affordable ... to the manager, reseller hosting is a very popular ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 ... Fenofibrate (CAS 49562-28-9) Industry, 2009-2019 is a ... and Chinese Fenofibrate (CAS 49562-28-9) industry. The ... Fenofibrate (CAS 49562-28-9) including its classification, application ... and China’s top manufacturers of Fenofibrate (CAS ...
(Date:9/21/2014)... 21, 2014 More than 60 ... added over the past month to a federal ... cardiovascular injuries caused by the dialysis concentrate, Bernstein ... on September 15th shows 2,089 cases filed in ... Court, District of Massachusetts. These claims were filed ...
Breaking Medicine News(10 mins):Health News:Cancer cells adapt energy needs to spread illness to other organs 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4Health News:Best Cheap Hosting USA Announces The Best Reseller Hosting Suppliers In 2014 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 2Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 3Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 4
... ... sugar and high in antioxidants. Summer is just around the corner so look and feel great ... the healthiest berry on earth! , ... York, NY (PRWEB) April 26, 2010 -- Move over acai, there’s a new berry in town ...
... degrees, for men with advanced disease, studies found, , ... this week of a therapeutic prostate cancer vaccine by ... milestone against the disease and cancer in general, experts ... survival in men with advanced prostate cancer, and it ...
... , ... at the recent 2010 DTC National Conference in Washington, D.C., agreed 2-1 that they would ... , ... Park, NJ (PRWEB) April 27, 2010 -- DTC Perspectives, Inc ., the leading conference, ...
... ... Exclusively at Target, with four all-natural treatment collections for all hair types and ethnicities. ... (PRWEB) April ... Care, which debuted exclusively in 233 Target stores on March 28, 2010. An ...
... ... their own custom branded mobile application to iPhone, iPad, and Android devices without having to ... ... its platform that allows businesses to build and deploy their own mobile application, ...
... ... to take place on May 6, 2010. Two years in the planning and development, ... center offers nonsurgical laser treatments for varicose veins and spider veins. , ... Prescott, AZ (PRWEB) April 27, 2010 -- Prescott ...
Cached Medicine News:Health News:Supercharge Summer with Superfood-infused Cookies! 2Health News:Supercharge Summer with Superfood-infused Cookies! 3Health News:Prostate Cancer Vaccine May Get FDA Approval 2Health News:Prostate Cancer Vaccine May Get FDA Approval 3Health News:Top DTC Marketers Choose Obama Over Romney and Palin 2Health News:Top DTC Marketers Choose Obama Over Romney and Palin 3Health News:Sundial Creations Announces the Debut of SheaMoisture Organic Hair Care Exclusively at Target 2Health News:Snowflake Mobile™ Launches Platform for Creating and Deploying Mobile Apps 2Health News:New Varicose Vein Treatment Center Opens in Prescott, Arizona 2
(Date:9/19/2014)... , Sept. 19, 2014 Today, iHealth Lab ... from Xiaomi Ventures, Ltd. for its first institutional round ... continue expanding iHealth,s global reach, accelerate growth and innovation, ... part of the investment, Xiaomi Ventures will join iHealth,s ... of cloud infrastructure and ecommerce. "We are ...
(Date:9/19/2014)... Kiromic, LLC, a Lubbock bio-pharmaceutical company, ... former chancellor of Texas Tech University, to its board as ... after raising $1.2 billion for the university. "Kiromic ... most successful chancellor in the history of Texas Tech University, ... but also as our new vice chairman of the board. ...
(Date:9/19/2014)... N.C. , Sept. 19, 2014  For ... cloud-based drug design and development, partnering is an ... mission is to design new drugs and identify ... 2 partners to further their development. The company ... investments. To support this business model, Cloud Pharmaceuticals ...
Breaking Medicine Technology:iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2
... Data in Pediatric Patients,Presented at the American ... N.J., Nov. 11 Daiichi Sankyo,Inc. (DSI), ... study supporting,the use of colesevelam HCl in ... presented for the first time at the,American ...
... 3.5 Fold Higher ... Compared to Standard Chemotherapy, SEATTLE, Nov. 11 ... it achieved the primary,efficacy endpoint of its phase III EXTEND ... non-Hodgkin,s,lymphoma (NHL) based on a preliminary intent to treat efficacy ...
Cached Medicine Technology:Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 2Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 3Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 4Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 5Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 6Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 7Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 2Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 3Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: